12.07.15
Innophos Nutrition Inc., North Salt Lake, UT, manufacturer and distributor of ingredients and blends to the nutritional and natural products industries, and a subsidiary of Innophos Holdings Inc., has signed an exclusive distribution agreement for the U.S. with Theravalues Corporation, Japan. The collaboration pairs Theravalues’ research and development expertise with the sales, marketing, and distribution infrastructure of Innophos Nutrition.
Innophos Nutrition will employ its sales, marketing, and distribution expertise and leverage the strength of its relationships with finished product manufacturers, to present and distribute Theracurmin and EMIQ, unique formulations shown through clinical studies to be ground-breaking nutritional ingredients.
In human clinical studies, Theracurmin is 27 times more bioavailable than standard curcumin powder. Dispersible in water, heat and light stable, it is ideal for a variety of delivery forms. One of the most researched curcumin ingredients on the market, Theracurmin has 19 completed human clinical trials and 15 ongoing studies to continue to show its benefits on human health.
Enzymatically-modified isoquercitrin (EMIQ) is a water-soluble polyphenol derived from rutin. In multiple human clinical studies, EMIQ is 17 times more bioavailable than quercetin. That research also indicates EMIQ increases markers of body fat metabolism and is a powerful antioxidant that supports the immune system and cellular health.
Bruce Brown, vice president, Innophos Nutrition, commented, "We are excited about the addition of Theracurmin and EMIQ into our signature ingredient portfolio. Theracurmin is the most clinically studied and versatile curcumin product on the market. EMIQ is a unique, water-soluble and highly active polyphenol. Both Theracurmin and EMIQ deliver superior health benefits and extensive formulation opportunities.”
Additionally, Joseph Golowski, president Innophos Nutrition, stated, “Theravalues Corporation shares our commitment to innovation and high-quality products. We look forward to working together as we provide customers with access to these exciting ingredients.”
Tadashi Hashimoto, representative director and president of Theravalues Corporation, commented “We developed patented technologies to make highly bioavailable Theracurmin and EMIQ, increasing bioavailability for more efficient dosages then invested in successful human clinical trials. I am confident and enthusiastic that this strategic partnership with Innophos Nutrition will accelerate the expansion of these fantastic ingredients and consequently, improve health and wellness of people in the USA.”
Innophos Nutrition will employ its sales, marketing, and distribution expertise and leverage the strength of its relationships with finished product manufacturers, to present and distribute Theracurmin and EMIQ, unique formulations shown through clinical studies to be ground-breaking nutritional ingredients.
In human clinical studies, Theracurmin is 27 times more bioavailable than standard curcumin powder. Dispersible in water, heat and light stable, it is ideal for a variety of delivery forms. One of the most researched curcumin ingredients on the market, Theracurmin has 19 completed human clinical trials and 15 ongoing studies to continue to show its benefits on human health.
Enzymatically-modified isoquercitrin (EMIQ) is a water-soluble polyphenol derived from rutin. In multiple human clinical studies, EMIQ is 17 times more bioavailable than quercetin. That research also indicates EMIQ increases markers of body fat metabolism and is a powerful antioxidant that supports the immune system and cellular health.
Bruce Brown, vice president, Innophos Nutrition, commented, "We are excited about the addition of Theracurmin and EMIQ into our signature ingredient portfolio. Theracurmin is the most clinically studied and versatile curcumin product on the market. EMIQ is a unique, water-soluble and highly active polyphenol. Both Theracurmin and EMIQ deliver superior health benefits and extensive formulation opportunities.”
Additionally, Joseph Golowski, president Innophos Nutrition, stated, “Theravalues Corporation shares our commitment to innovation and high-quality products. We look forward to working together as we provide customers with access to these exciting ingredients.”
Tadashi Hashimoto, representative director and president of Theravalues Corporation, commented “We developed patented technologies to make highly bioavailable Theracurmin and EMIQ, increasing bioavailability for more efficient dosages then invested in successful human clinical trials. I am confident and enthusiastic that this strategic partnership with Innophos Nutrition will accelerate the expansion of these fantastic ingredients and consequently, improve health and wellness of people in the USA.”
